e-selectin
Recombinant proteinexperimental
E-selectin, also known as CD62 antigen-like family member E (CD62E), endothelial-leukocyte adhesion molecule 1 (ELAM-1), or leukocyte-endothelial cell adhesion molecule 2 (LECAM2), is a selectin cell adhesion molecule expressed only on endothelial cells activated by cytokines. Like other selectins, it plays an important part in inflammation. In humans, E-selectin is encoded by the SELE gene. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00012454)
Timeline
Indications
Mechanism of action
- Selectin EINHIBITOR
SELE inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaE-selectin ↗
Also known as
- e-selectin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00069069 | Phase 1 | Sep 10, 2003 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00012454 | Phase 2 | Mar 1, 2001 | National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 2 | 2 | 2 | 2001 |
1 organizations
Page 1 / 1